BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35399022)

  • 21. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Common and distinct features of potentially predictive biomarkers in small cell lung carcinoma and large cell neuroendocrine carcinoma of the lung by systematic and integrated analysis.
    Dong S; Liang J; Zhai W; Yu Z
    Mol Genet Genomic Med; 2020 Mar; 8(3):e1126. PubMed ID: 31981472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
    Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
    Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary Large Cell Neuroendocrine Carcinoma.
    Yang L; Fan Y; Lu H
    Pathol Oncol Res; 2022; 28():1610730. PubMed ID: 36304941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Kinslow CJ; May MS; Saqi A; Shu CA; Chaudhary KR; Wang TJC; Cheng SK
    Clin Lung Cancer; 2020 Mar; 21(2):e99-e113. PubMed ID: 31601526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary large-cell neuroendocrine carcinoma of the parotid gland: immunohistochemical and molecular analysis of two cases.
    Nagao T; Sugano I; Ishida Y; Tajima Y; Munakata S; Asoh A; Yamazaki K; Muto H; Konno A; Kondo Y; Nagao K
    Mod Pathol; 2000 May; 13(5):554-61. PubMed ID: 10824928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring imaging features of molecular subtypes of large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Sanduleanu S; Derks JL; Woodruff H; Hillen LM; Casale R; Hoesein FM; de Jong E; Berge DMHJT; Speel EJM; Lambin P; Gietema HA; Dingemans AC
    Lung Cancer; 2020 Oct; 148():94-99. PubMed ID: 32858338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the molecular features and genetic prognostic factors of pulmonary high-grade neuroendocrine carcinomas.
    Wang H; Yan L; Zhu Y; Sun W; Yang X; Liu X; Chi K; Huang X; Zhou L; Lin D
    Hum Pathol; 2023 Dec; 142():81-89. PubMed ID: 37742943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated quantification of Ki-67 proliferative index of excised neuroendocrine tumors of the lung.
    Liu SZ; Staats PN; Goicochea L; Alexiev BA; Shah N; Dixon R; Burke AP
    Diagn Pathol; 2014 Oct; 9():174. PubMed ID: 25318848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
    Milione M; Maisonneuve P; Grillo F; Mangogna A; Centonze G; Prinzi N; Pusceddu S; Garzone G; Cattaneo L; Busico A; Bossi P; Spaggiari P; Pellegrinelli A; Del Gobbo A; Ferrero S; Kankava K; Pruneri G; Rolli L; Roca E; Bercich L; Tironi A; Benvenuti MR; Gallazzi MS; Romano R; Berruti A; Pastorino U; Capella C
    Neuroendocrinology; 2021; 111(5):475-489. PubMed ID: 32365350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
    Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma.
    Hiroshima K; Iyoda A; Shibuya K; Haga Y; Toyozaki T; Iizasa T; Nakayama T; Fujisawa T; Ohwada H
    Cancer; 2004 Mar; 100(6):1190-8. PubMed ID: 15022286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
    Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
    Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Large cell neuroendocrine carcinoma of the lung: a comparison with large cell carcinoma with neuroendocrine morphology and small cell carcinoma.
    Peng WX; Sano T; Oyama T; Kawashima O; Nakajima T
    Lung Cancer; 2005 Feb; 47(2):225-33. PubMed ID: 15639721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of SATB2 in Neuroendocrine Carcinomas of the Lung: Frequent Immunopositivity of Large Cell Neuroendocrine Carcinoma with a Diagnostic Pitfall.
    Inoue H; Matsushima J; Kobayashi S; Sairenchi T; Hirata H; Chida M; Ota S; Ban S; Matsumura Y
    Int J Surg Pathol; 2022 Apr; 30(2):151-159. PubMed ID: 34913369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.
    Travis WD; Linnoila RI; Tsokos MG; Hitchcock CL; Cutler GB; Nieman L; Chrousos G; Pass H; Doppman J
    Am J Surg Pathol; 1991 Jun; 15(6):529-53. PubMed ID: 1709558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. POU2F3-Expressing Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma Show Morphologic and Phenotypic Overlap.
    Jimbo N; Ohbayashi C; Takeda M; Fujii T; Mitsui S; Tsukamoto R; Tanaka Y; Itoh T; Maniwa Y
    Am J Surg Pathol; 2024 Jan; 48(1):4-15. PubMed ID: 37904277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.
    Hermans BCM; Derks JL; Hillen LM; van der Baan I; van den Broek EC; von der Thüsen JH; van Suylen RJ; Atmodimedjo PN; den Toom TD; Coumans-Stallinga C; Timens W; Dinjens WNM; Dubbink HJ; Speel EM; Dingemans AC;
    Int J Cancer; 2022 Mar; 150(5):802-815. PubMed ID: 34674268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.